HUE032747T2 - A 4-terc-butil-N-[4-kloro-2-(1-oxipiridin-4-karbonil)-fenil]-benzénszulfonamid nátriumsójának kristályos formája - Google Patents

A 4-terc-butil-N-[4-kloro-2-(1-oxipiridin-4-karbonil)-fenil]-benzénszulfonamid nátriumsójának kristályos formája Download PDF

Info

Publication number
HUE032747T2
HUE032747T2 HUE12741219A HUE12741219A HUE032747T2 HU E032747 T2 HUE032747 T2 HU E032747T2 HU E12741219 A HUE12741219 A HU E12741219A HU E12741219 A HUE12741219 A HU E12741219A HU E032747 T2 HUE032747 T2 HU E032747T2
Authority
HU
Hungary
Prior art keywords
amely amely
crystalline form
legalább legalább
compound
crystalline
Prior art date
Application number
HUE12741219A
Other languages
English (en)
Inventor
Andrew M K Pennell
Solomon Ungashe
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of HUE032747T2 publication Critical patent/HUE032747T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (6)

  1. $2ΑΒΑΙΜΙ,Ι4Ι IGÉNYRQNfCM vl^mantes kósiájyoa formép« ahölia iríilélyöi sugárzás alkalmazásával mért porféntgesi-diffrakcíós mintázattal ieifémezabk, amely legalább barom diífrakciészcgef magába foglal az alábbi csoportból K-választva; AJ: 9.1; 12,0; 14,2; 1ÏJ: 18.1; 10,2; 19,8; 20,1; 21,3; 22,5; 24,3; 27,0;. 27.2; 27J; 23 5 23,8 29 0 37 '1 0 ^3, 33 ? »s 3Γ 6 \)k 30 »0 2 <<'k 28 2. -M 1 - szabadalmi fgértyponf szebhiknsiáfyös farmé:, ahol a kbálltpt fermât p^^etgert-difmkälbeplili^Ä^iimmäk, amely loipsibb három didVakc-ószöget magába foglal ad afábbfbáoportból kivllaazlya: 4;7;:·#*1.1712,0; 14.2218.1 ; 11,2;;#«10,1;;27,2; 28 J ésÍ7j fok 28 ±0.2 fok 28, 3. Μ. 1. szabadaimr igertypoatazorioti kristályos ferma, áhol a kdatáípt fermât pbrtömgarr-dlfOákoiáa mibtlzátfal jatfemezzlk, amely legalább három diftakcibszögáf magába foglal az alábbi csoportból biváíasztve; 4,7; i 2,0; 14-2; 18.1.19.2 és 24,3 fok 20 £0,2 fok 28.
  2. 4. Az 1, szabadalmi igénypont szerinti kristályos forma, ahol; a kristályos formát pofíöntgen-diíffakciós rnintázabal jelfemezzök, amely alábbi csoportból magába:; 4,7; 12,8; 14,2, 18,1; 19,2 és 2,4.3 m m ao,2 m 2b.
  3. 5. Az 1-4, szabadalmi Igénypont szánok kristályos forma, ahol a kristályos formát Roma mspokf rummalpltemezzik, amely legalább három csúcsot magába foglal az alábbi esoportbbl kivilaaztob héíyzmekboo; §81, 832, :851, §84,726,745, 893, 851, 831,1080, 1123, 1738, 1162, 1318. 1398. 1458. 1526, 1595. 1614 és 1847 cnT ±4 cm’1.
  4. 6. .Az 1-5. szababelmi ígénpont szerinti kristályos forma, ahol a kristályos formât R a ma n -spa k mj m ma I je I le mázzák. rmiely legalább hárem csúcsot magaba foglal m alábbi psoportbórkfválaeziott belyzétakben: 884, 740, 883: 853 1030;, 1123, HM, 1118, 1458, 1528, 4895,1644 és 7, ·Μζ 1-6. szatedsirnî: igénypont szerinti krisiátps tonà, ahoi a kriátálpá forrót. . amely !êg|Â&amp;!Mfoi?ï csúcsot ***ä» fegiai m ää mspwmê mètemm neiyaeiahhem m4,1102, um, 1614 Is 164? οπΓ ±4 cm'·. 6-: Ax 1--6-, izatjadalmi igénypont: szerinti kristályos forma. ahol a kristályos formát Ramamspekirummat |ailgrhezzöio amely az alábbi esopo? fáét kiválasztott hepatakpéntévö csúcsokat fogat magába; 604, 740- 803, 85?. 1080.1123, 11027111:6,146:871626.1596,1614 és 1647 cm'; ±4 cm'l 9. 42; 1 -6, szaPadátmi tgáhyponiát lármolyif á46:4t4i tistiiyos főmét iá ^ÄP^riszeieg; tífdpdhafá vívó anyagot fartaimazö g pfpsorkészftmény,
  5. 10. Az 1-6. szahádelmi igénypontok bármelyike széhnti ^kristályos torma vagy a 9. iKftbittti igénypont ázéflnti készítmény a gyriadásos beibeiegsêg kezelésére, 11 · A IQ-: szabadálms igénypont Wtifi felhisznällsra Mént kristályos íömm vágy készítmény,: ahol a gyulladásos béibéispig: a örohn-beiegség vágy a colitis élőerőse köböl korúi kiválasztásra.
  6. 12. Mz 148. szabadalmi igénypontok bármelyike széfmíí kíisiályee forma Vágy 8 9, izasoadairm igénypont szerinti készítmény a Ibyetkeibk közöl kiválasztott, CCR-9 által médiáit állapotok kezelésére; szisztémás ansflíaxia, fálérzikenyslgí válaszok, gyógyszerallergiák, rovamsipêsekkai szembeni allergiák, ételallergiák, Orohsmbefegslg:, colitis ulcerosa. ileitis és enteritis, vaginis, psonaslm dementis, ekcéma, atdpiás dermatitis, allergiás kontakt dermatitis, urticaria, pruritus, vasculitis. spöndyládhrbpafhíák, scleroderma, asthma, ibrornyálgia, apiOfoaemia, spondylitis ankylepbetiea, juvenilis Ra, Still· betspégypoiyafieúlans juvenilis RA, paaeiartsouiana juvenilis :RA, polymyalgia rheumatlca, rheumatoid arthritis, arthritis penance, osfeaertbdha polyepicuianc arthritis, seiéresis multiplex, szisztémás lupus erythematosus, i ms típust oukOfiséiopèg, t-es típusú pkarbsiegség,, gtdmemlonaphniia, graftkiJOkidés, akut; is krúnikus graftmarsasmcsf betégsêg, atherosclerosis, myositis, Aizheimar-betegsóg, eneephakiic, meningitis. hepatitis, nephritis* sepsis, sarcoidysis, allergiás conjunctivitis omis. krónikus obstruktiv tüdőbetegség, sinusitis, Sáhcen kór, kószvény, puimonalts fibrosis és imláfcriis bei szindróma..
HUE12741219A 2011-07-22 2012-07-20 A 4-terc-butil-N-[4-kloro-2-(1-oxipiridin-4-karbonil)-fenil]-benzénszulfonamid nátriumsójának kristályos formája HUE032747T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161510832P 2011-07-22 2011-07-22

Publications (1)

Publication Number Publication Date
HUE032747T2 true HUE032747T2 (hu) 2017-10-30

Family

ID=46599010

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12741219A HUE032747T2 (hu) 2011-07-22 2012-07-20 A 4-terc-butil-N-[4-kloro-2-(1-oxipiridin-4-karbonil)-fenil]-benzénszulfonamid nátriumsójának kristályos formája

Country Status (20)

Country Link
US (1) US9133124B2 (hu)
EP (1) EP2748146B1 (hu)
JP (1) JP6122003B2 (hu)
CN (1) CN103842343B (hu)
AU (1) AU2012287160B2 (hu)
BR (1) BR112014001299B1 (hu)
CA (1) CA2841967C (hu)
DK (1) DK2748146T3 (hu)
ES (1) ES2625286T3 (hu)
HR (1) HRP20170745T1 (hu)
HU (1) HUE032747T2 (hu)
IL (1) IL230468B (hu)
MX (1) MX350269B (hu)
PL (1) PL2748146T3 (hu)
PT (1) PT2748146T (hu)
RS (1) RS56023B1 (hu)
RU (1) RU2607515C2 (hu)
SI (1) SI2748146T1 (hu)
WO (1) WO2013016174A1 (hu)
ZA (1) ZA201400474B (hu)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9150513B2 (en) * 2011-07-22 2015-10-06 Chemocentryx, Inc. Polymorphic forms of the sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzene sulfonamide
BR112014001530B1 (pt) * 2011-07-22 2022-05-31 Chemocentryx, Inc Formas polimórficas do sal de sódio de 4-terc-butiln-[4-cloro-2-(1-óxi-piridina-4-carbonil)- fenil]-benzeno sulfonamida, composição farmacêutica e método de produção da mesma
EP3141235A1 (en) * 2012-12-06 2017-03-15 IP Gesellschaft für Management mbH N-(6-((2r,3s)-3,4-dihydroxybutan-2-yloxy)-2-(4-fluorobenzylthio)pyrimidin-4-yl)-3-methylazetidine-l -sulfonamide
CA3125504C (en) 2013-03-14 2023-10-24 United Therapeutics Corporation Solid forms of treprostinil
KR102642382B1 (ko) 2014-10-06 2024-02-29 케모센트릭스, 인크. C-c 케모카인 수용체 타입 9 (ccr9)의 억제제 및 항-알파4베타7 인테그린 차단 항체의 조합 요법
US10792360B1 (en) 2019-11-21 2020-10-06 Chemocentryx, Inc. Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies
TW202203916A (zh) 2020-03-31 2022-02-01 美商卡默森屈有限公司 使用ｃｃｒ９抑制劑及抗ｉｌ—２３阻斷抗體治療發炎性腸道疾病的組成物及方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
FR2634376B1 (fr) 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
IT1227626B (it) 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DE69309056T2 (de) 1992-06-10 1997-09-18 Nanosystems Llc Oberflaechenmodifizierte nsaid nanopartikeln
AU660852B2 (en) 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5585108A (en) 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5571536A (en) 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5560931A (en) 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5503723A (en) 1995-02-08 1996-04-02 Eastman Kodak Company Isolation of ultra small particles
US5622938A (en) 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5565188A (en) 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5747001A (en) 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
CA2485681C (en) * 2002-05-24 2012-10-16 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
EP2256116A3 (en) * 2002-11-18 2011-11-16 ChemoCentryx, Inc. Aryl sulfonamides
JP2007527918A (ja) * 2004-03-08 2007-10-04 アムジェン インコーポレイテッド Ｐｐａｒガンマ活性の治療的調節
AU2005245401A1 (en) * 2004-05-12 2005-12-01 Chemocentryx Aryl sulfonamides
BRPI0714407A2 (pt) * 2006-07-14 2013-03-05 Chemocentryx Inc composto triazolil fenil benzeno-sulfonamida, composiÇço compreendendo o mesmo, usos do mesmo, mÉtodos de modulaÇço de funÇço de ccr2 e ccr9
WO2008008374A2 (en) * 2006-07-14 2008-01-17 Chemocentryx, Inc. Ccr2 inhibitors and methods of use thereof
US8519135B2 (en) * 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
BR112014001530B1 (pt) * 2011-07-22 2022-05-31 Chemocentryx, Inc Formas polimórficas do sal de sódio de 4-terc-butiln-[4-cloro-2-(1-óxi-piridina-4-carbonil)- fenil]-benzeno sulfonamida, composição farmacêutica e método de produção da mesma
US9150513B2 (en) * 2011-07-22 2015-10-06 Chemocentryx, Inc. Polymorphic forms of the sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzene sulfonamide

Also Published As

Publication number Publication date
CA2841967C (en) 2020-06-16
CN103842343A (zh) 2014-06-04
US9133124B2 (en) 2015-09-15
CA2841967A1 (en) 2013-01-31
HRP20170745T1 (hr) 2017-08-11
US20130059893A1 (en) 2013-03-07
PT2748146T (pt) 2017-05-29
SI2748146T1 (sl) 2017-10-30
IL230468A0 (en) 2014-03-31
JP2014524931A (ja) 2014-09-25
MX2014000660A (es) 2014-07-09
JP6122003B2 (ja) 2017-04-26
DK2748146T3 (en) 2017-05-22
BR112014001299B1 (pt) 2022-08-16
ZA201400474B (en) 2015-03-25
MX350269B (es) 2017-08-31
RU2014104993A (ru) 2015-11-20
IL230468B (en) 2018-05-31
ES2625286T3 (es) 2017-07-19
RS56023B1 (sr) 2017-09-29
RU2607515C2 (ru) 2017-01-10
AU2012287160A1 (en) 2014-02-06
BR112014001299A2 (pt) 2017-01-10
PL2748146T3 (pl) 2017-09-29
EP2748146B1 (en) 2017-03-08
WO2013016174A1 (en) 2013-01-31
AU2012287160B2 (en) 2017-02-02
EP2748146A1 (en) 2014-07-02
CN103842343B (zh) 2016-08-31

Similar Documents

Publication Publication Date Title
HUE032747T2 (hu) A 4-terc-butil-N-[4-kloro-2-(1-oxipiridin-4-karbonil)-fenil]-benzénszulfonamid nátriumsójának kristályos formája
US9809548B2 (en) Polymorphic forms of the sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzene sulfonamide
US9464054B2 (en) Polymorphic forms of the sodium salt of 4-tert-butyl-N-[4-CHLOR0-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide
JP5448197B2 (ja) Ｎ−［４−（トリフルオロメチル）ベンジル］−４−メトキシブチルアミドの新規な多形相